To provide the right treatment for MS, it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently recognized on average three years too late. Researchers at Uppsala University have now developed an AI model that can determine with 90 per cent certainty which variant the patient has. The model increases the chances of starting the right treatment in time and thus slowing the progression of the disease. Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. In Sweden, there are approximately 22,000 people living with MS. Most patients start with the relapsing-remitting form (RRMS), which is characterised by episodes of deterioration with intervening periods of stability. Over time, many people transition to secondary progressive MS (SPMS), where their symptoms instead get steadily worse, without obvious breaks. Identifying this transition is important because the two different forms of MS require different treatments. Currently, the diagnosis is made on average three years after the transition begins, which can lead to patients receiving medicines that are no longer effective. Based on Swedish MS data The new AI model summarizes clinical data from over 22,000 patients in the Swedish MS Registry. The model is based on data already collected during regular healthcare visits, such as neurological tests, magnetic resonance imaging (MRI) scans and ongoing treatments. "By recognizing patterns from previous patients, the model can determine whether a patient has the relapsing-remitting form or whether the disease has transitioned to secondary progressive MS. What is unique about the model is that it also indicates how confident it is in each individual assessment. This means that the doctor will know how reliable the conclusion is and how confident the AI is in its assessment," says Kim Kultima, who led the study. Ninety per cent accuracy In the study, now published in the journal Digital Medicine, the model identified the transition to secondary progressive MS correctly or earlier than documented in the patient's medical records in almost 87 per cent of cases, with an overall accuracy of around 90 per cent. "For patients, this means that the diagnosis can be made earlier, which makes it possible to adjust the patient's treatment in time and slow down the progression of the disease. This also reduces the risk of patients receiving medicines that are no longer effective. In the long term, the model could also be used to identify suitable participants for clinical trials - which could contribute to more effective and individualised treatment strategies," Kultima concludes.